ArticleBioprocess and biosystems engineering2025
Gamma-aminobutyric acid fermentation and its fermented extracts on α-glucosidase inhibition and anti-obesity effect.
Article in Bioprocess and biosystems engineering, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Levilactobacillus brevis KCL010 was fermented in a simple medium containing 8% (w/v) of rice bran extract. We modified the carbon, nitrogen, and initial pH conditions using 10 g/L of sucrose, 10 g/L of yeast extract, and 5.0 of pH, respectively. To minimize the pH increase due to decarboxylation, we fermented 100 mL of modified synthetic medium containing citrate-phosphate buffer (CPB, pH 5.0) of 25-200 mM in 250 mL Erlenmeyer flasks. After 72 h of fermentation with 50 mM CPB, the maximum GABA concentration and conversion efficiency were 3.42 g/L and 22.39%. Furthermore, the potential α-glucosidase inhibitory activity, MTT assay, and oil red O staining were determined by fermented extracts of L. brevis KCL010. At the highest concentration of 500 μg/mL, the α-glucosidase inhibition percentages for non-fermented rice bran (NFRB), rice bran fermented by L. brevis (RBFL), and GABA (analytical standard) extracts were 55.03%, 58.37%, and 59.48%, respectively. All extracts exceeded 80% viability, suggesting that there was no cytotoxic to 3T3-L1 adipocytes. The rice bran fermented by L. brevis (RBFL) extract shows a high inhibition of lipid accumulation by 29.33% compared to those of extracts.
Indexed as
Identifiers
39694912What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.